Negotiating excess treatment costs in a clinical research trial: the good, the bad and the innovative.
Trials
; 17: 71, 2016 Feb 09.
Article
em En
| MEDLINE
| ID: mdl-26860107
ABSTRACT
UNLABELLED Barriers to recovering the excess treatment costs associated with health research from local organisations in the United Kingdom can increase research costs, delay completion of high- quality studies and risk disenfranchising health trusts and patients from participation. The authors demonstrate how the process for recovering excess treatment costs at a local National Health Service (NHS) trust level in a multicentre study was inconsistent and resulted in excess effort and cost to the research budget. An innovative example of how an organisation acting as a broker between commissioners and researchers facilitated a more timely excess treatment cost agreement is highlighted. TRIAL REGISTRATION Current Controlled Trials ISRCTN68798818, registered on 18 February 2014.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Ensaios Clínicos como Assunto
/
Custos de Cuidados de Saúde
/
Pesquisa Biomédica
Tipo de estudo:
Health_economic_evaluation
Limite:
Humans
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article